AR082625A1 - HUMANIZED ANTIBODIES AGAINST EGFR - Google Patents
HUMANIZED ANTIBODIES AGAINST EGFRInfo
- Publication number
- AR082625A1 AR082625A1 ARP110102913A AR082625A1 AR 082625 A1 AR082625 A1 AR 082625A1 AR P110102913 A ARP110102913 A AR P110102913A AR 082625 A1 AR082625 A1 AR 082625A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- egfr
- heavy chain
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Anticuerpos humanizados anti-EGFR que presentan propiedades de unión al antígeno similares a las del anticuerpo anti-EGFR murino o quimérico del que derivan. Anticuerpos humanizados anti-EGFR que son útiles en el tratamiento del cáncer.Reivindicación 1: Un anticuerpo humanizado, o un fragmento o un derivado de éste, caracterizado porque puede unirse a un receptor del factor de crecimiento epidérmico (EGFR) y que comprende una región variable de la cadena pesada donde la CDR1 tiene la secuencia de aminoácidos de SEQ ID Nº 1, la CDR2 tiene la secuencia de aminoácidos de SEQ ID Nº 2 y la CDR3 tiene la secuencia de aminoácidos de SEQ ID Nº 3, y donde una o más de las regiones del marco de trabajo 1, 2 y 3 corresponden a las regiones del marco de trabajo de una región variable de la cadena pesada secuencia de aminoácidos que comprende SEQ ID Nº 31.Humanized anti-EGFR antibodies that exhibit antigen binding properties similar to those of the murine or chimeric anti-EGFR antibody from which they are derived. Humanized anti-EGFR antibodies that are useful in the treatment of cancer. Claim 1: A humanized antibody, or a fragment or derivative thereof, characterized in that it can bind to an epidermal growth factor receptor (EGFR) and comprising a region heavy chain variable where the CDR1 has the amino acid sequence of SEQ ID No. 1, the CDR2 has the amino acid sequence of SEQ ID No. 2 and the CDR3 has the amino acid sequence of SEQ ID No. 3, and where one or more of the framework regions 1, 2 and 3 correspond to the framework regions of a variable region of the heavy chain amino acid sequence comprising SEQ ID No. 31.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP110102913 AR082625A1 (en) | 2011-08-10 | 2011-08-10 | HUMANIZED ANTIBODIES AGAINST EGFR |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP110102913 AR082625A1 (en) | 2011-08-10 | 2011-08-10 | HUMANIZED ANTIBODIES AGAINST EGFR |
Publications (1)
Publication Number | Publication Date |
---|---|
AR082625A1 true AR082625A1 (en) | 2012-12-19 |
Family
ID=47562089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110102913 AR082625A1 (en) | 2011-08-10 | 2011-08-10 | HUMANIZED ANTIBODIES AGAINST EGFR |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR082625A1 (en) |
-
2011
- 2011-08-10 AR ARP110102913 patent/AR082625A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR109715A1 (en) | ANTI-CD27 ANTIBODIES | |
MY190771A (en) | Anti-pd-l1 antibodies and uses thereof | |
AR106184A1 (en) | PD-1 BINDING PROTEINS AND THEIR METHODS OF USE | |
CY1120414T1 (en) | ANTIBODIES CONNECTED TO NO40 AND THEIR USES | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
MX2020001873A (en) | Binding agents. | |
EA201791961A1 (en) | ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | |
PE20190976A1 (en) | ANTIBODIES OF UNION TO CD3 | |
NZ610734A (en) | Human antibodies to the glucagon receptor | |
PE20121649A1 (en) | MONOCLONAL ANTIBODIES TO PROGASTRIN AND ITS USES | |
AR084210A1 (en) | PROTEINS OF UNION TO TNF-a | |
PE20240218A1 (en) | AFFINITY MATURED AND HUMANIZED ANTIBODIES TO FCRH5 | |
AR099812A1 (en) | ANTI-EGFR ANTIBODY AND DRUG ANTIBODIES AND CONJUGATES | |
PE20221580A1 (en) | THERAPEUTIC ANTIBODIES AND THEIR USES | |
NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
ES2776179T3 (en) | Antibodies directed against surface determinants of S. aureus | |
NZ715896A (en) | Humanized or chimeric cd3 antibodies | |
NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
PE20141398A1 (en) | NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS | |
AR084141A1 (en) | ANTI-CCL20 NEUTRALIZING ANTIBODIES | |
NZ631007A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
CO6430469A2 (en) | HUMANIZED ANTIBODIES THAT JOIN CD19 AND ITS USES | |
CO6410312A2 (en) | ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR HUMAN OX40 | |
NZ605980A (en) | Anti-fap antibodies and methods of use | |
AR096617A1 (en) | ANTI-TWEAKR ANTIBODIES AND THEIR USES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |